Sanofi (France)-Genzyme Corporation’s MS Drug Lemtrada Beats Rebif in Head-to-head Phase III Showdown

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), reports today additional data from the Phase III CARE-MS II trial. Accumulation of disability was significa…
Read the full story: BioSpace.com Featured News